Literature DB >> 31196869

Vulvar melanoma: management of primary disease and repeated recurrences.

Salim Abraham Barquet-Munoz1, Mario Leitao2, Maria Delia Pérez Montiel3, Bernardino Gabriel Santiago Concha4.   

Abstract

Entities:  

Keywords:  melanoma; sentinel lymph node; surgical oncology

Mesh：

Year:  2019        PMID： 31196869      PMCID： PMC7425808          DOI： 10.1136/ijgc-2019-000610

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN： 1048-891X            Impact factor:   3.437


× No keyword cloud information.
  10 in total

1.  Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.

Authors:  Alexander M M Eggermont; Christian U Blank; Mario Mandala; Georgina V Long; Victoria Atkinson; Stéphane Dalle; Andrew Haydon; Mikhail Lichinitser; Adnan Khattak; Matteo S Carlino; Shahneen Sandhu; James Larkin; Susana Puig; Paolo A Ascierto; Piotr Rutkowski; Dirk Schadendorf; Rutger Koornstra; Leonel Hernandez-Aya; Michele Maio; Alfonsus J M van den Eertwegh; Jean-Jacques Grob; Ralf Gutzmer; Rahima Jamal; Paul Lorigan; Nageatte Ibrahim; Sandrine Marreaud; Alexander C J van Akkooi; Stefan Suciu; Caroline Robert
Journal:  N Engl J Med       Date:  2018-04-15       Impact factor: 91.245

2.  Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial.

Authors:  Ulrike Leiter; Rudolf Stadler; Cornelia Mauch; Werner Hohenberger; Norbert Brockmeyer; Carola Berking; Cord Sunderkötter; Martin Kaatz; Klaus-Werner Schulte; Percy Lehmann; Thomas Vogt; Jens Ulrich; Rudolf Herbst; Wolfgang Gehring; Jan-Christoph Simon; Ulrike Keim; Peter Martus; Claus Garbe
Journal:  Lancet Oncol       Date:  2016-05-05       Impact factor: 41.316

3.  Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.

Authors:  Mark B Faries; John F Thompson; Alistair J Cochran; Robert H Andtbacka; Nicola Mozzillo; Jonathan S Zager; Tiina Jahkola; Tawnya L Bowles; Alessandro Testori; Peter D Beitsch; Harald J Hoekstra; Marc Moncrieff; Christian Ingvar; Michel W J M Wouters; Michael S Sabel; Edward A Levine; Doreen Agnese; Michael Henderson; Reinhard Dummer; Carlo R Rossi; Rogerio I Neves; Steven D Trocha; Frances Wright; David R Byrd; Maurice Matter; Eddy Hsueh; Alastair MacKenzie-Ross; Douglas B Johnson; Patrick Terheyden; Adam C Berger; Tara L Huston; Jeffrey D Wayne; B Mark Smithers; Heather B Neuman; Schlomo Schneebaum; Jeffrey E Gershenwald; Charlotte E Ariyan; Darius C Desai; Lisa Jacobs; Kelly M McMasters; Anja Gesierich; Peter Hersey; Steven D Bines; John M Kane; Richard J Barth; Gregory McKinnon; Jeffrey M Farma; Erwin Schultz; Sergi Vidal-Sicart; Richard A Hoefer; James M Lewis; Randall Scheri; Mark C Kelley; Omgo E Nieweg; R Dirk Noyes; Dave S B Hoon; He-Jing Wang; David A Elashoff; Robert M Elashoff
Journal:  N Engl J Med       Date:  2017-06-08       Impact factor: 91.245

Review 4.  Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma.

Authors:  Andrea Ladányi
Journal:  Pigment Cell Melanoma Res       Date:  2015-04-20       Impact factor: 4.693

5.  Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases.

Authors:  Priyadharsini Nagarajan; Jonathan L Curry; Jing Ning; Jin Piao; Carlos A Torres-Cabala; Phyu P Aung; Doina Ivan; Merrick I Ross; Charles F Levenback; Michael Frumovitz; Jeffrey E Gershenwald; Michael A Davies; Anais Malpica; Victor G Prieto; Michael T Tetzlaff
Journal:  Clin Cancer Res       Date:  2016-11-18       Impact factor: 12.531

6.  Sentinel-node biopsy or nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Robert Elashoff; Richard Essner; Omgo E Nieweg; Daniel F Roses; Harald J Hoekstra; Constantine P Karakousis; Douglas S Reintgen; Brendon J Coventry; Edwin C Glass; He-Jing Wang
Journal:  N Engl J Med       Date:  2006-09-28       Impact factor: 91.245

7.  Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.

Authors:  Alexander M M Eggermont; Vanna Chiarion-Sileni; Jean-Jacques Grob; Reinhard Dummer; Jedd D Wolchok; Henrik Schmidt; Omid Hamid; Caroline Robert; Paolo A Ascierto; Jon M Richards; Céleste Lebbé; Virginia Ferraresi; Michael Smylie; Jeffrey S Weber; Michele Maio; Lars Bastholt; Laurent Mortier; Luc Thomas; Saad Tahir; Axel Hauschild; Jessica C Hassel; F Stephen Hodi; Corina Taitt; Veerle de Pril; Gaetan de Schaetzen; Stefan Suciu; Alessandro Testori
Journal:  N Engl J Med       Date:  2016-10-07       Impact factor: 91.245

Review 8.  Vulvar malignant melanoma: Pathogenesis, clinical behaviour and management: Review of the literature.

Authors:  Florine L Boer; Mieke L G Ten Eikelder; Ellen H Kapiteijn; Carien L Creutzberg; Khadra Galaal; Mariette I E van Poelgeest
Journal:  Cancer Treat Rev       Date:  2018-12-24       Impact factor: 12.111

9.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.

Authors:  Jeffrey Weber; Mario Mandala; Michele Del Vecchio; Helen J Gogas; Ana M Arance; C Lance Cowey; Stéphane Dalle; Michael Schenker; Vanna Chiarion-Sileni; Ivan Marquez-Rodas; Jean-Jacques Grob; Marcus O Butler; Mark R Middleton; Michele Maio; Victoria Atkinson; Paola Queirolo; Rene Gonzalez; Ragini R Kudchadkar; Michael Smylie; Nicolas Meyer; Laurent Mortier; Michael B Atkins; Georgina V Long; Shailender Bhatia; Celeste Lebbé; Piotr Rutkowski; Kenji Yokota; Naoya Yamazaki; Tae M Kim; Veerle de Pril; Javier Sabater; Anila Qureshi; James Larkin; Paolo A Ascierto
Journal:  N Engl J Med       Date:  2017-09-10       Impact factor: 91.245

10.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.

Authors:  Georgina V Long; Axel Hauschild; Mario Santinami; Victoria Atkinson; Mario Mandalà; Vanna Chiarion-Sileni; James Larkin; Marta Nyakas; Caroline Dutriaux; Andrew Haydon; Caroline Robert; Laurent Mortier; Jacob Schachter; Dirk Schadendorf; Thierry Lesimple; Ruth Plummer; Ran Ji; Pingkuan Zhang; Bijoyesh Mookerjee; Jeff Legos; Richard Kefford; Reinhard Dummer; John M Kirkwood
Journal:  N Engl J Med       Date:  2017-09-10       Impact factor: 91.245
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.